Advanced Malignant Tumor Clinical Trial
Official title:
A Phase I Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of QLS31901 for Injection in Patients With Advanced Malignant Tumors
This is a Phase 1, open label, non-randomised, dose-escalation single agent study with expansion cohorts for dose confirmation/safety and preliminary efficacy of QLS31901 in advanced or metastatic malignancies
Study Design: This open label, multicenter, first in human study consists of 2 parts. Part 1 is a dose escalation to find the recommended dose for the expansion. Part 2 is a dose expansion to confirm the dose of QLS31901 through further evaluation of safety, tolerability, Pk, preliminary antitumor activity, and functional target engagement. The study includes three periods: Screening( up to 28 days prior to the first dose of study drug); Treatment(first dose of study drug with treatment cycles of 28 days); and Follow-up ( 30days 、60days and 90 days after the last dose) including survival follow-up checks every 3 months up to 12 months after the death of patient or the end of this clinical trial . ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05015309 -
A Study to Investigate Safety and Tolerability of SH3765 Tablet in Patients With Advanced Malignant Tumor
|
Phase 1 | |
| Not yet recruiting |
NCT06022250 -
The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant Tumor
|
Phase 1 | |
| Recruiting |
NCT06059508 -
Phase I Clinical Study of SHR-5495 in the Treatment of Patients With Advanced Malignant Tumors
|
Phase 1 | |
| Recruiting |
NCT05851092 -
Phase I Clinical Study of HRS-2189 in the Treatment of Patients With Advanced Malignant Tumors
|
Phase 1 | |
| Suspended |
NCT05089461 -
A Study to Evaluate the Cardiac Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Malignant Tumor
|
Phase 2 | |
| Active, not recruiting |
NCT04296994 -
A Study of QL1706 in Subjects With Advanced Malignant Tumor
|
Phase 1 | |
| Recruiting |
NCT05416359 -
Phase I Clinical Trial of TQB3915 Tablets in Subjects With Advanced Malignant Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04326829 -
QL1604 Monotherapy for dMMR or MSI-H Advanced Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT04739111 -
An Exploratory Clinical Study of LDP Combined With CDP1 in Patients With Advanced Malignant Tumor
|
Phase 1 | |
| Recruiting |
NCT05767060 -
BAT7104 Injection in Patients With Advanced Malignant Tumors.
|
Phase 1 | |
| Recruiting |
NCT04975204 -
A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant Tumors
|
Phase 1 | |
| Recruiting |
NCT05144061 -
A First-in-human Study of HRS2398 Tablets in Subjects With Advanced Malignant Tumors
|
Phase 1 | |
| Recruiting |
NCT04412564 -
A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor
|
Phase 2 | |
| Recruiting |
NCT05198505 -
Clinical Trial of TQB2868 Injection in Subjects With Advanced Malignant Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT05318833 -
A Study of HRS7415 Tablets in Patients With Advanced Malignant Tumors
|
Phase 1 |